Britain's research-based pharmaceutical industry has been accused of using devious tactics to extend the life of drug patents, costing the NHS millions of pounds. Manufacturers of generic medicines - cheap copies of brand-name drugs - hit out at the tactics adopted by major pharmaceutical companies of "evergreening" products to maintain their monopoly on the market after a patent expires.
Discuss   Add this link to...  Bury

Comments Who Voted Related Links